Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.61 |
| ▸ | HTR2C | P28335 | 9/20 | 0.50 |
| ▸ | HTR2B | P41595 | 8/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002059 | 0.96 | HTR2A (0.59) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL26056042 | 0.92 | HTR2A (0.64) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL26056043 | 0.85 | HTR2A (0.59) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002187 | 0.84 | HTR2A (0.58) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002101 | 0.83 | HTR2A (0.57) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970965 | 0.82 | HTR2A (0.55) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002131 | 0.81 | HTR2A (0.54) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002147 | 0.80 | HTR2A (0.52) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL20970884 | 0.79 | HTR2A (0.58) | HTR2AHTR2CHTR2BKDM4EATM | |
| SCHEMBL27002196 | 0.79 | HTR2A (0.37) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| EP-4305019-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192781-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | HTR2A 11/4885HTR2C 3/4885HTR2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.